E. Anders Kolb

11.8k citations

285 papers · 6.5k · h-index 47

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
Oncology top 1%
- CAR-T cell therapy research

Papers in

Molecular Biology 117
- Protein Degradation and Inhibitors 25
- Cancer therapeutics and mechanisms 20
- Histone Deacetylase Inhibitors Research 17
Hematology 107
- Acute Myeloid Leukemia Research 94

Co-authors: Richard Görlick (103 shared papers)Peter J. Houghton (87 shared papers)Malcolm A. Smith (96 shared papers)John M. Maris (80 shared papers)Stephen T. Keir (70 shared papers)C. Patrick Reynolds (70 shared papers)Richard B. Lock (65 shared papers)Christopher L. Morton (48 shared papers)
Journals: Pediatric Blood & Cancer (86 papers)Blood (65 papers)Cancer Research (14 papers)Journal of Clinical Oncology (14 papers)Molecular Cancer Therapeutics (13 papers)
Partner nations: United States Australia Canada

In The Last Decade

E. Anders Kolb

271 papers receiving 6.4k citations

Peers

Countries citing papers authored by E. Anders Kolb

Since Specialization

Citations

This map shows the geographic impact of E. Anders Kolb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Anders Kolb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Anders Kolb more than expected).

Fields of papers citing papers by E. Anders Kolb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Anders Kolb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Anders Kolb. The network helps show where E. Anders Kolb may publish in the future.

Co-authors

The 25 scholars most cited alongside E. Anders Kolb, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E. Anders Kolb Line = papers co-authored together E. Anders Kolb links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 285 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Dickkopf 3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt-β-Catenin Pathway Cancer Research ·Bang H. Hoang, Tadahiko Kubo, John H. Healey, Rui Yang, Saminathan S. Nathan, E. Anders Kolb, BethAnne Mazza, Paul A. Meyers, Richard Görlick	2004	235
2	Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) Pediatric Blood & Cancer ·John M. Maris, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Richard B. Lock, Hernán Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Jianrong Wu, Malcolm A. Smith, Peter J. Houghton	2010	187
3	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program Pediatric Blood & Cancer ·E. Anders Kolb, Richard Görlick, Peter J. Houghton, Christopher L. Morton, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Catherine A. Billups, Malcolm A. Smith	2008	144
4	Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing’s Family of Tumors in Children and Young Adults Journal of Clinical Oncology ·E. Anders Kolb, Brian H. Kushner, Richard Görlick, Caroline Laverdière, John H. Healey, Michael P. LaQuaglia, Andrew G. Huvos, Jing Qin, Ha Thanh Vu, Leonard H. Wexler, Suzanne L. Wolden, Paul A. Meyers	2003	138
5	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program Pediatric Blood & Cancer ·Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Görlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Catherine A. Billups, Malcolm A. Smith	2007	136
6	MicroRNAs and Potential Targets in Osteosarcoma: Review Frontiers in Pediatrics ·Valerie B. Sampson, Soonmoon Yoo, Asmita Kumar, Nancy S. Vetter, E. Anders Kolb	2015	135
7	Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy Cancer Research ·Christopher C. Mills, E. Anders Kolb, Valerie B. Sampson	2018	116
8	Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program Pediatric Blood & Cancer ·Richard B. Lock, Hernán Carol, Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Görlick, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	2007	105
9	Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program Pediatric Blood & Cancer ·John M. Maris, Joshua Courtright, Peter J. Houghton, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Richard B. Lock, Mayamin Tajbakhsh, C. Patrick Reynolds, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	2007	104
10	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program Pediatric Blood & Cancer ·Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Nino Keshelava, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	2007	103
11	Parallel Randomized Trials of Risk-Based Therapy for Fetal Alloimmune Thrombocytopenia Obstetrics and Gynecology ·Richard L. Berkowitz, E. Anders Kolb, Janice G. McFarland, Megan Wissert, Andrea Primani, Martin Lesser, James B. Bussel	2006	103
12	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group Haematologica ·Richard Aplenc, Soheil Meshinchi, Lillian Sung, Todd A. Alonzo, John Choi, Brian T. Fisher, Robert B. Gerbing, Betsy Hirsch, Terzah M. Horton, Samir B. Kahwash, John E. Levine, Michael R. Loken, Lisa Eidenschink Brodersen, Jessica A. Pollard, Susana C. Raimondi, E. Anders Kolb, Alan S. Gamis	2020	95
13	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program Clinical Cancer Research ·Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Görlick, Hernán Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton	2014	93
14	Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States Pediatric Blood & Cancer ·Michele A. Scialla, Kimberly S. Canter, Fang Fang Chen, E. Anders Kolb, Eric Sandler, Lori Wiener, Anne E. Kazak	2017	87
15	The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML Blood ·Emily Heikamp, Jill A. Henrich, Florian Perner, Eric Wong, Charlie Hatton, Yanhe Wen, Sonali P. Barwe, Anilkumar Gopalakrishnapillai, Haiming Xu, Hannah J. Uckelmann, Sumiko Takao, Yaniv Kazansky, Yana Pikman, Gerard M. McGeehan, E. Anders Kolb, Alex Kentsis, Scott A. Armstrong	2021	86
16	Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program Pediatric Blood & Cancer ·Peter J. Houghton, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, John M. Maris, Jianrong Wu, Malcolm A. Smith	2010	85
17	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program Molecular Cancer Therapeutics ·Peter J. Houghton, Christopher L. Morton, Richard Görlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, Jianrong Wu, Amy Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith	2010	83
18	Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer Cancer Chemotherapy and Pharmacology ·Hernán Carol, Ingrid Boehm, C. Patrick Reynolds, Min H. Kang, John M. Maris, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Stephen T. Keir, Jianrong Wu, A. E. Wozniak, Yu Yang, Mark Manfredi, Jeffrey Ecsedy, Jianmin Wang, Geoffrey Neale, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	2011	83
19	Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia Leukemia ·Nicole McNeer, John Philip, Heather Geiger, Rhonda E. Ries, Vincent‐Philippe Lavallée, Michael F. Walsh, Minita Shah, Kanika Arora, Anne‐Katrin Emde, Nicolas Robine, Todd A. Alonzo, E. Anders Kolb, Alan S. Gamis, Malcolm A. Smith, Daniela S. Gerhard, Jaime Guidry-Auvil, Soheil Meshinchi, Alex Kentsis	2019	82
20	Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program Pediatric Blood & Cancer ·E. Anders Kolb, Richard Görlick, Peter J. Houghton, Christopher L. Morton, Geoffrey Neale, Stephen T. Keir, Hernán Carol, Richard B. Lock, Doris A. Phelps, Min H. Kang, C. Patrick Reynolds, John M. Maris, Catherine A. Billups, Malcolm A. Smith	2010	82

About E. Anders Kolb

E. Anders Kolb is a scholar working on Molecular Biology, Hematology, Oncology, Public Health, Environmental and Occupational Health and Pulmonary and Respiratory Medicine, having authored 285 papers that have together received 6.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (94 papers), Acute Lymphoblastic Leukemia research (31 papers), Protein Degradation and Inhibitors (25 papers), Neuroblastoma Research and Treatments (20 papers), CAR-T cell therapy research (20 papers), Cancer therapeutics and mechanisms (20 papers), Cancer Genomics and Diagnostics (17 papers) and Histone Deacetylase Inhibitors Research (17 papers). The work is most often cited by research in Hematology (1.2k citations), Oncology (1.5k citations), Cancer Research (824 citations), Neurology (732 citations) and Pulmonary and Respiratory Medicine (1.2k citations). E. Anders Kolb has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Richard Görlick, Peter J. Houghton, Malcolm A. Smith, John M. Maris, Stephen T. Keir, C. Patrick Reynolds, Richard B. Lock, Christopher L. Morton, Hernán Carol and Min H. Kang. Their work appears in journals such as Pediatric Blood & Cancer, Blood, Cancer Research, Journal of Clinical Oncology and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

E. Anders Kolb

Impact in

Papers in i

In The Last Decade

E. Anders Kolb

Peers

Countries citing papers authored by E. Anders Kolb

Fields of papers citing papers by E. Anders Kolb

All Works

About E. Anders Kolb

Explore authors with similar magnitude of impact

Papers in